These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
170 related articles for article (PubMed ID: 37277843)
41. Invasive meningococcal disease in England and Wales: implications for the introduction of new vaccines. Ladhani SN; Flood JS; Ramsay ME; Campbell H; Gray SJ; Kaczmarski EB; Mallard RH; Guiver M; Newbold LS; Borrow R Vaccine; 2012 May; 30(24):3710-6. PubMed ID: 22429756 [TBL] [Abstract][Full Text] [Related]
42. Estimating primary care attendance rates for fever in infants after meningococcal B vaccination in England using national syndromic surveillance data. Harcourt S; Morbey RA; Bates C; Carter H; Ladhani SN; de Lusignan S; Smith GE; Elliot AJ Vaccine; 2018 Jan; 36(4):565-571. PubMed ID: 29246475 [TBL] [Abstract][Full Text] [Related]
43. Acute cerebellitis in adults: a case report and review of the literature. Van Samkar A; Poulsen MNF; Bienfait HP; Van Leeuwen RB BMC Res Notes; 2017 Nov; 10(1):610. PubMed ID: 29166939 [TBL] [Abstract][Full Text] [Related]
44. A randomized, controlled trial to assess the immunogenicity and safety of a heptavalent diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, hib and meningococcal serogroup C combination vaccine administered at 2, 3, 4 and 12-18 months of age. Szenborn L; Czajka H; Brzostek J; Konior R; Caubet M; Ulianov L; Leyssen M Pediatr Infect Dis J; 2013 Jul; 32(7):777-85. PubMed ID: 23838777 [TBL] [Abstract][Full Text] [Related]
49. Potential public health impact of a Huang L; Snedecor SJ; Balmer P; Srivastava A Postgrad Med; 2022 May; 134(4):341-348. PubMed ID: 33615973 [TBL] [Abstract][Full Text] [Related]
50. Effectiveness and impact of the 4CMenB vaccine against invasive serogroup B meningococcal disease and gonorrhoea in an infant, child, and adolescent programme: an observational cohort and case-control study. Wang B; Giles L; Andraweera P; McMillan M; Almond S; Beazley R; Mitchell J; Lally N; Ahoure M; Denehy E; Koehler A; Flood L; Marshall H Lancet Infect Dis; 2022 Jul; 22(7):1011-1020. PubMed ID: 35427492 [TBL] [Abstract][Full Text] [Related]
51. Evolving strategies for meningococcal vaccination in Europe: Overview and key determinants for current and future considerations. Martinón-Torres F; Taha MK; Knuf M; Abbing-Karahagopian V; Pellegrini M; Bekkat-Berkani R; Abitbol V Pathog Glob Health; 2022 Mar; 116(2):85-98. PubMed ID: 34569453 [TBL] [Abstract][Full Text] [Related]
52. Epidemiological impact and cost-effectiveness of universal vaccination with Bexsero(®) to reduce meningococcal group B disease in Germany. Christensen H; Irving T; Koch J; Trotter CL; Ultsch B; Weidemann F; Wichmann O; Hellenbrand W Vaccine; 2016 Jun; 34(29):3412-9. PubMed ID: 27109566 [TBL] [Abstract][Full Text] [Related]
53. Multicomponent meningococcal serogroup B vaccination elicits cross-reactive immunity in infants against genetically diverse serogroup C, W and Y invasive disease isolates. Biolchi A; De Angelis G; Moschioni M; Tomei S; Brunelli B; Giuliani M; Bambini S; Borrow R; Claus H; Gorla MCO; Hong E; Lemos APS; Lucidarme J; Taha MK; Vogel U; Comanducci M; Budroni S; Giuliani MM; Rappuoli R; Pizza M; Boucher P Vaccine; 2020 Nov; 38(47):7542-7550. PubMed ID: 33036804 [TBL] [Abstract][Full Text] [Related]
54. Meningococcal B vaccination coverage among older adolescents in the United States. La EM; Garbinsky D; Hunter S; Poston S; Novy P; Ghaswalla P Vaccine; 2021 May; 39(19):2660-2667. PubMed ID: 33849722 [TBL] [Abstract][Full Text] [Related]
55. Severe cerebellar atrophy following acute cerebellitis. Hayakawa H; Katoh T Pediatr Neurol; 1995 Feb; 12(2):159-61. PubMed ID: 7779216 [TBL] [Abstract][Full Text] [Related]
56. Single priming dose of meningococcal group C conjugate vaccine (NeisVac-C®) in infants. Poellabauer EM; Pavlova BG; Fritsch S; Singer J; Neubauer C; Doralt J; Valenta-Singer B; Ehrlich HJ Vaccine; 2013 Aug; 31(35):3611-6. PubMed ID: 23672977 [TBL] [Abstract][Full Text] [Related]
57. Potential Coverage of the 4CMenB Vaccine against Invasive Serogroup B Mulhall RM; Bennett D; Cunney R; Borrow R; Lucidarme J; Findlow J; Jolley KA; Bray J; Maiden MCJ; Moschioni M; Serino L; Stella M; Medini D mSphere; 2018 Aug; 3(4):. PubMed ID: 30135218 [No Abstract] [Full Text] [Related]
58. Severe Upper Extremity Dysfunction After 4CMenB Vaccination in a Young Infant. Tenenbaum T; Niessen J; Schroten H Pediatr Infect Dis J; 2016 Jan; 35(1):94-6. PubMed ID: 26379162 [TBL] [Abstract][Full Text] [Related]
59. Autoimmune Cerebellar Ataxia: Etiology and Clinical Characteristics of a Case Series from China. Liu M; Ren H; Zhu Y; Fan S; Bai L; Wang J; Cui L; Guan H Cerebellum; 2023 Jun; 22(3):379-385. PubMed ID: 35618871 [TBL] [Abstract][Full Text] [Related]
60. Immunogenicity and safety of MenACWY-TT, a meningococcal conjugate vaccine, co-administered with routine childhood vaccine in healthy infants: A phase III, randomized study. Dbaibo G; Tinoco Favila JC; Traskine M; Jastorff A; Van der Wielen M Vaccine; 2018 Jun; 36(28):4102-4111. PubMed ID: 29784470 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]